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New guidelines for the administration of amikacin are presented for neonates,
children and adults, with normal or impaired, stable or changing renal function.
The dose is calculated according to the lean body mass, which can be estimated
from weight, height and sex of the patient. The dosing interval is calculated from
the predicted drug half-life, which is derived from creatinine clearance normalized
to 50 kg lean body mass (LBM). A formula is presented to estimate directly the
CCT in ml/min per 50 kg LBM, based only upon serum creatinine concentrations
and the age of the subject Two electronic pocket calculators which contain the
dosage guidelines of amikacin are also described.
Les auteurs presenters de nouvelles recommandations pour la determination de la
posologie de l'amikacine chez les nouveau-nes, les enfants et les adultes dans le cas
de fonction r£nale normale ou alt6r6e, de facon stable ou variable.
La dose est calculee selon la masse corporelle 'degraisseV qui est evaluee en
fonction du poids, de la taille et du sexe du malade. L'intervalle entre les doses est
calculi a partir de la demi-vie cstimee selon la valeur de la clairance de la
creatinine rapport6e a 50 kg de masse corporelle ld6graisseV.
Une formule est donn£e, qui permet de calculer directement la clairance de la
creatinine en ml/min/50 kg de masse corporelle degraissee basie uniquement sur
la creatininemie et l'age du sujet.
Deux calculateurs de poche programmers pour le calcul de la posologie de
l'amikacine sont decrites.
Introdnction
All drug dosage rules are originally based upon the drug half-life. However, the
direct measurement of the drug half-life is not always possible, because serum
assays are not always available for each drug. Even if the serum drug levels can be
obtained, corrections can only be done after the dosage regimen has been applied.
l
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No information on the dosage regimen can be given before the first dose. Further-
more, quality-control surveys on aminoglycosides have shown that only a few
laboratories appear to be capable of producing accurate results (Reeves & Bywater,
1975). Even in specialized laboratories errors of more than 100% often occur (Pijck
& Hallynck, 1981). It is, therefore, not surprising that dosage guidelines are not^
directly based upon drug half-life, but on serum creatinine concentrations (£„), or
on creatinine clearance (CCT) determinations or estimations.
With all dosage guidelines, it is essential that similar drug half-lives should be
obtained, when SCT or Ccr are the same in two individuals. Only with CCT, normalized
to 50 kg lean body mass (LBM), do similar half-lives of amikacin, gentamicin and
tobramycin occur with identical Ccr, independently of the age of the patient.
Gentamicin half-lives, estimated from Ccr expressed in ml/min or in ml/min per
1-73 m2 body surface area (BSA) can be quite different from the measured half-life,
especially in neonates and children. Only with CCT, normalized to 50 kg LBM,
can reliable estimations of gentamicin half-lives be obtained independent of the age
of the subject (Hallynck etai, 1981)
Materials and methods
In five independent centres (Brugge, Belgium; Perugia, Italy; Prague,
Czechoslovakia; Rouen, France; Tel Aviv, Israel), 62 patients were treated with
amikacin. Four centres treated 48 patients by intravenous administration (iv) and
one centre used the intramuscular route (i.m.) in 14 patients. Most of the patients
(53) had serious Gram-negative infections of the urinary tract; 3 suffered from
respiratory illness and 6 patients had sepsis. Of the patients, 19% were chronically
infected. Seventeen patients had a Ccr below 30 ml/min. The age of the patients
ranged from 19-82 years. Each patient received a loading dose of 75 (iv) or 10
(i.m.) mg/kg LBM. The individual LBM was calculated from skinfold measurements
as reported previously (Hallynck et al., 1980).
Determination of the individual LBM
The method for the determination of the LBM, used in this multi-centre trial of
amikacin in renal patients is too complex for routine use in clinical practice.
Furthermore, the method is only valid in adults (Hallynck et al., 1980): another
graph and another place on the body (triceps) are required for skinfold measure-
ments in children. Because of the practicality and the good correlation with the
skinfold technique, we suggest that the LBM in neonates, children and adults should
be calculated from the following formula, which is based upon the work of James
(1976):
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formales: LBM= 110 W- 128 -h~
for females: LBM = 107 H^- 148
where LBM = lean body mass in kg, W= weight in kg, H= height in cm.
As in the formula of Dubois & Dubois (1916) for the estimation of the body
surface area, the formula presented is based upon the weight and the height of the
subject. This has one major disadvantage: any overweight of the subject will be
converted by the formula into an excess of body fat, even if the overweight is due to
an excess of muscle. However, even in athletes, an excess of muscle is usually
accompanied by a large amount of body fat, so that for most individuals, the
formula presented can still be used. Only in some individuals, for example
professional football players, is an excess of musculature together with a decreased
amount of body fat sometimes found (Behnke & Willmore, 1975).
The dosage rules for amikacin were based upon the predicted drug half-life and
normalized CCT, calculated from a daily Scr determination and the age of the patient.
In patients with normal renal function, amikacin was given in doses of 75 (i.v.) or 10
(i.m.) mg/kg LBM every 12 h. In patients with impaired renal function, the dose was
reduced to three-quarters of the loading dose. The dosage interval was calculated as
twice the individual drug half-life of amikacin and rounded up to the nearest usual
dosage interval: 12,24,36,48,72 h, or longer.
Each day, serum and complete 24 h urine collections were sampled and frozen at
-20*C. Only after the study was finished, were all these samples analysed to measure
the daily 24-h endogenous Ccr and to construct three amikacin serum curves, each
with five points, at the beginning, middle and end period of therapy. The aim of the
proposed schedule was to obtain peak levels of 25 ± 5 mg/1 and trough levels
below 5 ± 2 mg/1. It was also possible to compare afterwards, for the three periods
mentioned, the drug half-life with the measured 24-h endogenous Ccr in ml/min and
with the CCT in ml/min per 50 kg LBM, which was estimated during the study and on
which the dosage schedule was based during the 8 days of therapy.
Prediction of the half-life of drugs
The half-life of drugs, partly or mainly excreted by the kidneys, can be estimated for
each individual (neonate, child or adult) from Ccr, when Ccr is normalized to 50 kg
LBM:
7% = -
where 7V2 = half-life of the drug in hours, Ft = renal correlation factor of drug
elimination and Ccr, FnT = non-renal correlation factor of drug elimination and Ccr.
For amikacin: FT= 171, Fm = 1. A list of Ft and Fm of more than 250 drugs is in
preparation.
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Figure 1. Determination of creatinine clearance in ml/min per 50 kg LBM.
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Estimation ofC^ in ml/min per 50 kg LBM
With stable serum creatinine levels (fluctuations below 0 5 mg/100 ml), CCT can be
estimated by:
Ccr = f- ml/min per 50 kg LBM (Hallynck et al., 1981).
Where Ccr = creatinine clearance in ml/min per 50 kg LBM, E = urinary creatinine
excretion obtainable from Figure 1, 5= measured serum creatinine in mg/100 ml.
When the renal function is not stable and Sa changes with at least 0-5 mg/100 ml,
Ccr can be estimated by:
CCT = - | - + 600. ' " 2 ml/min per 50 kg LBM (Hallynck et al., 1981).
Ccr = creatinine clearance in ml/min per 50 kg LBM,
E= urinary creatinine excretion obtainable from Figure 1,
5", = first serum creatinine concentration in mg/100 ml,
S2 = second serum creatinine concentration in mg/100 ml,
S = mean of 5, and S2.
T= time interval between 5, and S2 in hours.
Results
A cure rate of 75% with a low incidence of toxicity (2*3%) was noted. Eighty-six of
124 serum amikacin peaks (70%) lay between 20 and 30 mg/1, and 112 (90%)
between 15 and 30 mg/1. Only 3 (24%) peaks were higher than 35 mg/1. For trough
levels, 105 (83%) were found below 7 mg/1 and 117 (93%) out of 126 below 10 mg/1
(Boelaert etal., 1980).
The amikacin half-life correlated significantly better (P < 0-02 two-sided /-test)
with the estimated Ccr in ml/min per 50 kg LBM (r = 0'94) than with the measured
24-h endogenous CCT(r = 077)
No particular trend, decrease or increase of Ccr compared with the original kidney
function, was found. Over-all, in 27 patients the CCT improved during therapy, with
an average of 30% above the base-line level. In 16 patients, Ccr dropped, averaging
12% below the starting value. In two patients, Ccr improved significantly (> 250%)
during therapy, and only in one patient, did CCT drop to 58% of the original value.
This patient was considered as developing possible nephrotoxicity.
In four patients mildly impaired hearing was reported during treatment. However,
no difference was found between the follow-up period and the periods before and
after treatment. In one patient, vestibular function became normal 1 month after the
end of the therapy.
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Discussion
Prediction of drug half-life
When Ccr is normalized to the same distribution volume (e.g. 50 kg LBM), the
following formulae are valid, independently of the age and the renal disease of the
subject (Hallynck etal, 1981).
Kt = Km + KT = Knt + a. CCT (Dettli, 1977)
n.693
0693 a Fr
'T
+ CC
Ke = total first-order elimination rate constant,
Km = non-renal first-order elimination constant,
Kr = renal first-order elimination constant,
a = proportionality constant relating the renal elimination rate constant of a drug
and the creatinine clearance,
Ccr = creatinine clearance in ml/min per 50 kg LBM,
7 % = drug half-life,
FT = renal correlation factor of drug elimination Ca,
FnT = non-renal correlation factor of drug elimination and CCT.
Creatinine clearance expressed as ml/min per 50 kg lean body mass (LBM)
After Mclntosh et aL(1928) recommended amrea clearance normalized toil 73 m2
body surface area (BSA), the normalization of renal, hepatic or body clearance to
BSA became a standard method.
However, to compare clearance values in different individuals it would be more
logical to normalize the clearance to a standard distribution volume to be cleared.
Since the mean lean body mass (LBM) of a 25-year-old adult is about 50 kg, this
value was chosen to calculate the standard distribution volume for hydrophilic
compounds (drugs and body metabolites). Furthermore, in contrast with the BSA,
the LBM is linearly related to the distribution volume of hydrophilic compounds
(Hallynck etal., 1980).
When creatinine clearance values are correlated with drug half-lives, it is
particularly important to normalize the clearance values to 50 kg LBM. Otherwise,
quite different drug half-life values will be obtained in two individuals having
different drug distribution volumes even though they may have the same creatinine
clearance values.
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Dosage guidelines
With the guidelines presented, the actual amount of drug given is decreased and the
dosing interval is prolonged. In this way, long periods of both unduly high serum
concentrations and of sub-inhibitory concentrations will not occur. Within certain
limits (see Appendix) the dosing interval can be freely chosen so that practicable
times of drug administration can be selected. With a chosen dosing interval, the
maintenance dose can be calculated exactly to provide reproducible serum peak
levels after each drug administration. When the pocket dosing calculator is not
available, the size of the maintenance dose can be taken as either three-quarters of
the loading dose or the same as the loading dose, respectively, depending on whether
the chosen dosing interval is nearer to 2 or to 3 times the drug half-life.
An important finding of this study was that therapeutic serum levels were
obtained in patients with non-stable, as well as in those with stable, renal function.
Furthermore, the low incidence of nephrotoxicity (2-3%) is notable in view of the
fact that the majority of these patients had impaired renal function.
Appendix
Practical applications for amikacin
As a result of more than 5 years' experience with amikacin, we suggest the following
dosage guidelines:
(1) If the pocket dosing calculator is available
Two different pocket calculators have been programmed for amikacin dosage
guidelines. The calculators are commercially available (Hewlett-Packard HP-41C
and Tandy TRS80) with an alpha-numeric display and a continuous memory up to
2 Kbytes. On the display, the calculator asks the user consecutively 'weight in kg (or
lb)', 'height in cm (or inches)?',... etc., and gives the specific dosage guidelines for
the chosen patient, e.g. first dose = 1*9 ml; maintenance dose = 1-7 ml every 24 h.
In contrast to the manual method, the calculators correct for oedema, for
decreases in the apparent intramuscular distribution volume in severely affected
renal patients, and make a more accurate estimation of the maintenance dose:
^m = amount of drug in the maintenance dose,
A = amount of drug in the loading dose,
e = = relative dosing interval (e is at least 2)
7%7
T = chosen dose-interval in hours,
7V2 = drug half-life in hours.
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(2) If the pocket dosing calculator is NO T available
STEP 1: Estimate the LBM of the patient
formales: LBM = 110 W-128 —( in kg)
for females: LBM = 1 07 W - 148 -£- (in kg).
The mean LBM of an adult male is 80% and that of a female 75% of the total body
weight.
STEP 2: Calculate the loading dose (£>,)
Z), = LBMx 10(inmg).
STEP 3: Calculate the creatinine clearance (CCT) using Figure 1
CC T=-£- (mJ/min per 50 kg LBM).
STEP 4: Predict the drug half-life 7V,
STEP 5: Choose a practical dosing interval (at least and as closely as possible to
2 x 7V2) among every 12, 24, 36, 48, 72, 96 h or any other intermediate practicable
interval.
STEP 6: Calculate the maintenance dose (Dm = 3/4 Dh if the chosen interval is closer
to2x 7% or Dm = Dx if the chosen interval is closer to 3 x V/2
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